

headache, nausea, or vomiting was present, a physician should be consulted immediately.

DISPOSITION: 3-23-61. Default—destruction.

6558. Think-Eze tablets. (F.D.C. No. 45272. S. No. 17-684 R.)

QUANTITY: 73 100-tablet btl., 446 48-tablet btl., 394 24-tablet btl., and 287 8-tablet pkgs., at Denver, Colo.

SHIPPED: On 8-2-60 and dates subsequent thereto, from Huntington Park, Calif., by Retail Distributors Service, Inc.

LABEL IN PART: (Btl. and pkg.) "Think-Eze has a Tranquilizer action—An Aid To Relieve Nervous Tensions and help to obtain Normal Steady Nerves * * * Aldan Distributors, Inc., New York, N.Y. Long Beach, Calif. * * * Each Think-Eze tablet contains: Thiamine HCl (Vit. B-1) 1 mg. Niacinamide 5 mg. Ammonium and Sodium Bromides 4.75 gr. blended in a specially formulated and prepared inert base containing: Salicylamide, Glycyrrhiza Extract, Valerian Root, Pleurisy Root, Humulus Lupulus, Extract of Jamaica Dogwood."

ACCOMPANYING LABELING: Window banners reading in part "Think-Eze Tablets . . . With * * * Tranquilizer Action" and a number of large and small display units.

LIBELED: 12-7-60, Dist. Colo.

CHARGE: 502(a)—when shipped and while held for sale, the labeling of the article contained false and misleading representations that the article was adequate and effective as a treatment for nervous tensions, emotionally upset stomach, mental depression, and nerve-racking headaches; 502(a)—the statement "Tranquilizer" appearing on the labels and in the accompanying labeling when read in the setting in which presented, represented and suggested that the article would produce all of the effects capable of being produced by a commonly accepted true "tranquilizer" drug, whereas, the article was not a "tranquilizer" drug and would not produce all of the effects capable of being produced by a true "tranquilizer," and it would not provide the tranquilizing benefits claimed for it; 502(c)—the ingredient information required under 502(e) (2) and the warnings required by 502(f) (2) to appear in the labeling of the article were not prominently placed on the label and labeling with such conspicuousness, as compared with other statements on the label and labeling, as to render such information and warnings likely to be read and understood by the ordinary individual under customary conditions of purchase and sale; and 502(f) (2)—the labeling of the article failed to warn that it should not be given to children, and that its use should be discontinued if nervous symptoms persisted, recurred frequently, or were unusual.

DISPOSITION: 3-20-61. Default—destruction.

6559. Analjel. (F.D.C. No. 45189. S. No. 20-039 R.)

QUANTITY: 396 btl. at Lorain, Ohio.

SHIPPED: 8-16-60, from Pittsburgh, Pa., by the Federal Rice Drug Co.

LABEL IN PART: (Btl.) "Analjel a Nongreasy Analgesic Balm 2 Oz. Detroit First Aid Co., Detroit, Michigan Contents: Methyl Salicylate, Natural Menthol, Camphor, Oil of Peppermint."

LIBELED: 1-3-61, N. Dist. Ohio.

CHARGE: 502(a)—when shipped, the bottle label contained false and misleading representations that the article was an adequate and effective treatment

for rheumatism, neuritis, sprains, colds, etc.; and 502(f) (2)—the labeling failed to warn that the article should not be used otherwise than as directed; that it should be kept out of the reach of children; and that its use should be discontinued if excessive irritation of the skin developed.

DISPOSITION: 2-8-61. Default—destruction.

6560. Figurama device. (F.D.C. No. 42969. S. No. 27-707 P.)

QUANTITY: 20 devices individually cartoned at St. Paul and Minneapolis, Minn.

SHIPPED: 1-27-59 and 1-29-59, from Milford, Conn.

LABEL IN PART: "Tempulse Figurama By Streamform Corp., New York, N.Y."

RESULTS OF INVESTIGATION: Examination indicated that the device was a streamlined box-shaped housing containing an electric motor which provided vibrating and/or oscillating action to two pads located atop the housing. The pads contained a controlled heating element; and detachable tubular padded extensions converted the housing to a table-type device.

LIBELED: 4-7-59, Dist. Minn.

CHARGE: 502(f) (1)—while held for sale, the labeling of the article failed to bear adequate directions for use as a treatment for relieving polio or any disease of that type; reducing; easing an incurable disease; relieving arthritis, bursitis, rheumatism, and neuritis; increasing blood circulation to all parts of the body to keep one from becoming sick, losing hair, getting wrinkles, or having high blood pressure; improving posture and firming the body tissues; banishing nervous tension; as a "help for everything"; spot reducing and taking off inches; which were the conditions and purposes for which it was offered in oral statements made by a sales representative in Minneapolis, Minn., on 2-2-59 and 2-3-59.

DISPOSITION: In May 1959, the Streamform Corp. filed a claim to the articles. Thereafter, the action was removed at the claimant's motion to the United States District Court of New Jersey where an answer was filed by the claimant denying that the articles were misbranded. After further litigation including the submission of written interrogatories by the Government, the submission of answers by the claimant, a motion by the Government to compel further and more complete answers, and an order of the court that the claimants submit further and more complete answers, a consent decree of condemnation was filed on 10-20-60. The claimant failed to file the bond required by the consent decree for the release of the goods to the claimant for relabeling under Government supervision. A default decree was filed on 1-27-61, and the devices were ordered to be turned over to the Department of Health, Education, and Welfare, Food and Drug Administration, Minneapolis, Minn., for exhibit purposes.

6561. Ultra-Sonic device. (F.D.C. No. 44591. S. No. 43-699 R.)

QUANTITY: 1 device at Great Falls, Mont., in possession of Elizabeth Webb Hill.

SHIPPED: 8-14-59, from Los Angeles, Calif., by Ace Medical Instrument Co.

LABEL IN PART: (Metal plate on device) "Ace Ultra-Sonic * * * Manufactured by Electronics Instrument Co., Los Angeles, Calif."

ACCOMPANYING LABELING: Leaflets entitled "Operating Instructions" and "Ace Ultra-Sonic Deluxe Model."

RESULTS OF INVESTIGATION: Examination indicated the device to be an electronic device producing ultrasound energy at 960,000 cycles per second through a 10 square centimeter sound head. The instrument cabinets con-